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A 56-year-old man was referred to our clinic because of left lumbar pain and a left solitary renal tumor
(9. 8 cm in diameter) and bilateral pulmonary metastases detected by computed tomographic scan.
Pathologic diagnosis following open radical nephrectomy was papillary renal cell carcinoma, G2,
pT2aN0M1. Subsequently, the patient was sequentially treated with interleukin-2 (3 months (mo),
progressive disease (PD)), interferon-alpha (3 mo, PD), and oral S-1 as a clinical trial (28 mo, PD). Because of
skin fibrofolliculomas, pulmonary cysts, and spontaneous pneumothorax history, Birt-Hogg-Dubé (BHD)
syndrome was suspected during the treatment course, despite his having no family history of the disease.
Subsequent genetic testing revealed a FLCN germline mutation (c. 1285dupC). He was started on
molecular-targeting therapies sequentially, i.e., sorafenib (1 mo, PD), sunitinib (4 mo, PD), and everolimus (7
mo, PD). The patient died of progressive disease at 78 mo from the initial nephrectomy and 30 mo from the
start of targeted agents. Loss of FLCN function has been shown to result in the upregulation of the
PI3K/mTORC1 pathway in both in vitro experiments and in vivo FLCN knockout mice models. Despite
its use as the sixth-line systematic treatment, the mTOR inhibitor everolimus exhibited a relatively long-term
effect as compared with the previously used tyrosine kinase inhibitors and in contrast to the results in the
RECORD-1 clinical trial. This finding may provide insight into the molecular mechanism of BHD-
associated renal tumors.
(Hinyokika Kiyo 59 : 503-506, 2013)















画像所見 : 胸部―骨盤単純 CT．左腎に 9.8×6.3











術後経過 : 多発肺転移に対し，全身療法として IL-2
（35万単位・週 2回）を開始したが 3カ月評価で PD
(RECIST v 1.1 評価，以下同様）であった．引き続き
IFNα（500万国際単位・週 3回）に切り替えたがやは







Fig. 1. Chest-abdominal CT (plain). (a) A left kid-
ney tumor (9.8×6.3 cm) presented hetero-
geneous density. (b) and (c) Multiple me-
tastases and bullas in the bilateral lung fields.
り 3カ月で PD となり終了．その後 S-1 の臨床試験に
参加，途中気胸を発症し，縫縮手術などで一時休薬期






Fig. 2. Pathologic findings. Papillary RCC, G2,
pT2a.
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Fig. 3. Germline mutational analysis of the FLCN
gene. Sequence analysis revealed (c.














(G3），白血球減少 (G2) がみられたため，10，5 mg
の隔日投与で13カ月間治療を継続した．効果は best




BHD 症候群は1977年に Birt，Hogg，Dubé により
報告された常染色体優性遺伝性の腫瘍性疾患であり，
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は exon 11 のシトシンが 8回繰り返される，いわゆる
C (8) hotspot 内のもっとも頻度が高い変異であり，
疾患病態としては腎腫瘍の合併頻度が30％以上と高い
ことが知られている8)．
最近の遺伝子機能解析では，FLCN が FNIP1/2 と結










などの TKI は VHL/HIF 経路の下流に位置する
VEGFR や PDGFR を主に阻害し血管新生を抑制して
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